NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Sustained Release Injectable Drugs

出版商 Greystone Research Associates 商品編碼 996110
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
持續釋放注射 Sustained Release Injectable Drugs
出版日期: 2021年03月18日內容資訊: 英文





  • 注射藥物的市場動態
  • 自我管理趨勢
  • 注射技術
  • 注射裝置設計創新
  • 驅動治療藥物需求的因素
  • 市場因素
  • 競爭形勢
  • 危險因素
  • 品牌SR(持續釋放)注射技術
  • 可生物降解的聚合物
  • 品牌SR配方技術
  • 如何控制物理過程
  • 持續釋放注射劑:發展因素
  • 配方係數
    • 穩定
      • 凍乾
      • 包裝
  • 管理因素
  • SR注入:產品分析和現場預測
  • 成癮
    • 納曲酮
  • 糖尿病
    • 艾塞那□
  • 傳染病
    • 干擾素
  • 激素缺乏
    • 雌二醇
    • 生長激素
    • 睪丸激素
  • 代謝性疾病
    • 肢端肥大症
      • 蘭瑞□
      • 奧曲□
  • 神經症
    • 阿立□唑
    • 氟苯那秦
    • 氟□啶醇
    • 帕潘立酮
    • 奧氮平
    • 利培酮
  • 腫瘤
  • 白血病
    • 長春新鹼
  • 淋巴瘤
    • 阿糖胞甘
  • 前列腺
    • 戈瑟瑞林
    • 碘化鋰
    • 雷公籐甲素
  • 疼痛管理
    • 布比卡因
  • 生殖健康
  • 子宮內膜異位


Product Code: SRJ2M5K

Engineered Injectables that Address Chronic Conditions

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with less-frequent dosing.

What You Will Learn:

  • What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?
  • What are the major factors driving sustained release injectable drug demand?
  • What sustained release injectable drug candidates are in late-stage clinical development and what is their potential impact?
  • How important are drug developer-formulation technologist relationships in the sustained release market segment, and what are the key alliances in the industry?
  • What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for sustained release injectable drug products?
  • In what therapeutic market segments do sustained release injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate?
  • What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables?

Table of Contents

Executive Summary

  • Injectable Drug Market Dynamics
  • The Trend toward Self-Administration
  • Injectable Drug Formulation Technology
  • Innovation in Injectable Device Designs
  • Therapeutic Demand Drivers
  • Market Factors
  • Competitive Landscape
  • Risk Factors
  • Sustained Release - Branded Formulation Technologies
  • Biodegradable Polymers
  • Branded SR Formulation Technologies
  • Physical Process Control Methods
  • Sustained Release Injectables - Development Factors
  • Formulation Factors
    • Stability
      • Lyophilization
      • Packaging
  • Administration Factors
  • SR Injectables - Product Analysis & Market Sector Forecasts
  • Addiction
    • Naltrexone
  • Diabetes
    • Exenatide
  • Infectious Disease
    • Interferon
  • Hormone Deficiency
    • Estradiol
    • Somatropin
    • Testosterone
  • Metabolic Diseases
    • Acromegaly
      • Lanreotide
      • Octreotide
  • Neurology
    • Aripiprazole
    • Fluphenazine
    • Haloperidol
    • Paliperidone
    • Olanzapine
    • Risperidone
  • Oncology
  • Leukemia
    • Vincristine
  • Lymphoma
    • Cytarabine
  • Prostate
    • Goserelin
    • Leuprolide
    • Triptorelin
  • Pain Management
    • Bupivacaine
  • Reproductive Health
  • Endometriosis

Company Profiles